Rheumatology: a force for change in monoclonal antibodies.

abstract：:Stimulant use disorders are an unrelenting public health concern worldwide. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. The present paper reviewed clinical data from human laboratory self-administration studies and cl...

journal_title：Current pharmaceutical design

authors： Stoops WW,Rush CR

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Central serous chorioretinopathy (CSC) is the fourth most frequent retinal disorder in terms of prevalence. It typically occurs in young subjects and affects men more often than women. CSC is characterized by serous retinal detachment (SRD) involving mainly the macular area. The clinical course is usually se...

journal_title：Current pharmaceutical design

authors： Iacono P,Toto L,Costanzo E,Varano M,Parravano MC

更新日期：2018-01-01 00:00:00

abstract：:Research on Substance P (SP) has, until recently, focused on its role in pain and inflammation. However, a report that NK(1) receptor antagonists have utility in the treatment of depression has stimulated research into the function of SP and the NK(1)receptor in anxiety and depression. The distribution of SP and the N...

journal_title：Current pharmaceutical design

authors： McLean S

更新日期：2005-01-01 00:00:00

abstract：:The three opioid receptors, mu, delta and kappa all mediate analgesia, and knockout mice with opioid receptor deletion have proven unique tools to investigate in vivo opioid pharmacology. Since a few years, a number of new mouse lines have been engineered, with several distinct mutations of the mu receptor, to assess ...

journal_title：Current pharmaceutical design

authors： Gavériaux-Ruff C

更新日期：2013-01-01 00:00:00

abstract：:Improvements in our understanding of the intrinsic aberrancies in cancer cells have enabled the design and development of novel therapeutics that specifically target these changes. Among the many complex cellular pathways and mechanisms which have been unveiled by new molecular techniques, RAS-mediated signal transduc...

journal_title：Current pharmaceutical design

authors： Nottage M,Siu LL

更新日期：2002-01-01 00:00:00

abstract：:Over the past five decades, the pharmacological treatment of depression has been based on the pathophysiological hypothesis of a deficiency in monoamines, mainly serotonin and noradrenaline. Antidepressant prescribed today, all of them designed to enhance central monoaminergic tone, present several important limitatio...

journal_title：Current pharmaceutical design

authors： Vidal R,Pilar-Cuéllar F,dos Anjos S,Linge R,Treceño B,Vargas VI,Rodriguez-Gaztelumendi A,Mostany R,Castro E,Diaz A,Valdizán EM,Pazos A

更新日期：2011-01-01 00:00:00

abstract：:The majority of pharmaceutical formulations for the treatment of ocular pathologies are for topical administration. However, this kind of ophthalmic formulations has disadvantages such as low bioavailability and, consequently, a reduced therapeutic effect. This happens due to the anatomical and physiological specifici...

journal_title：Current pharmaceutical design

authors： Almeida H,Amaral MH,Lobao P,Frigerio C,Sousa Lobo JM

更新日期：2015-01-01 00:00:00

abstract：:Ischaemic stroke of the brain accounts for about one third of all deaths in industrialized countries. Many of the patients who survive are severily impaired. Thus, there is an enormous need for pharmacotherapy for the treatment of ischaemic stroke. Why is such a treatment not available yet? Are the pathophysiological ...

journal_title：Current pharmaceutical design

authors： Weiser T

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Polycystic ovary syndrome (PCOS) is a frequent female reproductive endocrine disease. It has been associated with a number of severe reproductive and metabolic abnormalities. However, there are still open questions especially regarding the best long-term management. METHODS:We summarized the literature focu...

journal_title：Current pharmaceutical design

authors： Ruan X,Li M,Mueck AO

更新日期：2018-01-01 00:00:00

abstract：:Alzheimer's disease (AD) is a heterogeneous and progressive neurodegenerative disease which in Western society mainly accounts for clinical dementia. Inflammation plays a key role in AD and dissecting the genetics of inflammation may provide an answer to the possible treatment. Hence, the better understanding of diffe...

journal_title：Current pharmaceutical design

authors： Balistreri CR,Grimaldi MP,Chiappelli M,Licastro F,Castiglia L,Listì F,Vasto S,Lio D,Caruso C,Candore G

更新日期：2008-01-01 00:00:00

abstract：:Both high arterial blood pressure (BP) and elevated levels of fine particulate matter (PM2.5) air pollution have been associated with an increased risk for several cardiovascular (CV) diseases, including stroke, heart failure, and myocardial infarction. Given that PM2.5 and high BP are each independently leading risk ...

journal_title：Current pharmaceutical design

authors： Giorgini P,Di Giosia P,Grassi D,Rubenfire M,Brook RD,Ferri C

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:A mobile health application is an exciting, fast-paced domain that is likely to improve prenatal care. METHODS:In this narrative review, we summarise the use of mobile health applications in this setting with a special emphasis on both the benefits of remote monitoring devices and the potential pitfalls of ...

journal_title：Current pharmaceutical design

authors： Gyselaers W,Lanssens D,Perry H,Khalil A

更新日期：2019-01-01 00:00:00

abstract：:The cytokine tumor necrosis factor(alpha) (TNF(alpha)) is associated with a constellation of physiological and behavioral characteristics that follow in response to infection such as fever, fatigue, listlessness, loss of appetite, malaise, and tactile hypersensitivity. These responses are examples of central nervous s...

journal_title：Current pharmaceutical design

authors： Hermann GE,Holmes GM,Rogers RC

更新日期：2005-01-01 00:00:00

abstract：:The clinically most relevant medications for lipid management are the statins, which constitute in the majority of the cases the basis of any lipid-modulating therapy. However, other agents are often needed to either reduce low-density cholesterol to target levels and/or to treat residual serum lipoprotein abnormaliti...

journal_title：Current pharmaceutical design

authors： Gouni-Berthold I,Berthold HK

更新日期：2013-01-01 00:00:00

abstract：:Type 2 diabetes is associated with substantially increased cardiovascular mortality. The need to reduce the progression of atherosclerosis alongside lowering blood glucose levels is now well established. Ideally, pharmaceutical treatment should address both of these needs. This review summarises current evidence of th...

journal_title：Current pharmaceutical design

authors： Papanas N,Maltezos E

更新日期：2009-01-01 00:00:00

abstract：:Fever of Unknown Origin, or FUO, is a challenging condition for patients and clinicians. In up to 50% of cases, no diagnosis is established. Patient workup begins with comprehensive history, physical examination and laboratory tests. Radionuclide imaging has been a second-line procedure. Gallium-67 citrate, which accu...

journal_title：Current pharmaceutical design

authors： Palestro CJ,Love C

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Coronavirus Disease-2019 belongs to the family of viruses which cause a serious pneumonia along with fever, breathing issues and infection of lungs for the first time in China and later spread worldwide. OBJECTIVE:Several studies and clinical trials have been conducted to identify potential drugs and vaccin...

journal_title：Current pharmaceutical design

authors： Bibi S,Sarfraz A,Mustafa G,Ahmed Z,Zeb MA,Wang YB,Khan T,Khan MS,Kamal MA,Yu H

更新日期：2020-11-17 00:00:00

abstract：:During the last decade immunomodulatory treatments have been shown to influence the natural course of multiple sclerosis (MS). However, demyelination in the central nervous system (CNS) still occurs and repair mechanisms are incomplete leading to neurological deficits. Currently, there is no therapy available to promo...

journal_title：Current pharmaceutical design

authors： Trebst C,Stangel M

更新日期：2006-01-01 00:00:00

abstract：:The development of targeted therapy drugs acting on tumor growth and progression is greatly expanding these last years. Among them kinase inhibitors have a prominent position and have demonstrated efficacy and clinical benefits in solid and hematologic malignancies. Compared to conventional systemic cytotoxic chemothe...

journal_title：Current pharmaceutical design

authors： Levade M,Severin S,Gratacap MP,Ysebaert L,Payrastre B

更新日期：2016-01-01 00:00:00

abstract：:Gene therapy may be capable of treating a variety of diseases, a prerequisite of which is the successful delivery of polynucleic acids (e.g., DNA, RNA) to a patient's cells. Delivery can be achieved technologically (e.g., using electroporation), using viruses (natural gene delivery vectors) or non-viral vectors (e.g.,...

journal_title：Current pharmaceutical design

authors： Clancy KFA,Hardy JG

更新日期：2017-01-01 00:00:00

abstract：:More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such ...

journal_title：Current pharmaceutical design

authors： Liu Z,Zhang J,Zhang A

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Ulinastatin (UTI) plays the beneficial roles in modifying cerebral ischemic injury evoked by cardiac arrest (CA). XueBiJing (XBJ), comprised of extracts from Chinese herbals, has been used for the treatment of sepsis and ischemic disorders linked to multiple organ dysfunction syndromes. The current study was...

journal_title：Current pharmaceutical design

authors： Ma C,Han DF,Jin H,Cheng YY,Hu HX,Wang X

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Bio-soft material, a class of derivatives of the natural or synthetic material, is getting more and more prevalent in biomedical researches and applications due to the advantages such as in-vivo biodegradation, good water solubility and designable targeting ability. With the presence of bio-sof...

journal_title：Current pharmaceutical design

authors： Chen N,Su T,Cheng Z,An F

更新日期：2018-01-01 00:00:00

abstract：:Psoriasis is an immune-mediated, chronic and recurrent inflammatory skin disease, prevalent worldwide, and represents an important burden in life quality of patients. The most common clinical variant is termed as psoriasis vulgaris or plaque psoriasis, which with an individualized and carefully monitored therapy can d...

journal_title：Current pharmaceutical design

authors： Bruschi ML,da Silva JB,Rosseto HC

更新日期：2019-01-01 00:00:00

abstract：:After years of pre-clinical and clinical testing monoclonal antibodies (mAbs) finally offer new therapeutic choices for patients with haematological and solid malignancies both as unconjugated antibody and as vectors to target radionuclides in radioimmunotherapy (RIT). In recent years some of the most exciting clinica...

journal_title：Current pharmaceutical design

authors： Illidge TM,Brock S

更新日期：2000-09-01 00:00:00

abstract：:Unlike other neuroinflammatory disorders, like Parkinson's disease, Huntington's disease and multiple sclerosis, little is still known of the role of the endocannabinoid system in Alzheimer's disease (AD). This is partly due to the poor availability of animal models that are really relevant to the human disease, and t...

journal_title：Current pharmaceutical design

authors： Bisogno T,Di Marzo V

更新日期：2008-01-01 00:00:00

abstract：:Multiple Sclerosis (MS) is the most common autoimmune demyelinating disorder in Western countries and can lead to permanent disability. Over the past decades remarkable progress has been made in providing new therapeutic strategies to tackle the burden of the disease. Oral drugs and monoclonal antibodies are the main ...

journal_title：Current pharmaceutical design

authors： Sanvito L,Constantinescu CS,Gran B

更新日期：2011-01-01 00:00:00

abstract：:Development of effective drug delivery systems is important for medicine and healthcare. Polymer particulates (micro- and nanoparticles) have opened new opportunities in the field of drug delivery by overcoming various limitations of conventional delivery methods. The properties of polymeric particles can be readily t...

journal_title：Current pharmaceutical design

authors： Kaur H,Kumar V,Kumar K,Rathor S,Kumari P,Singh J

更新日期：2016-01-01 00:00:00

abstract：:By updating John Littleton's work published 15 years ago this review summarizes recent work on pharmacodynamic aspects of acamprosate and the perspective for future developments. In addition to insights into the role of glutamatergic receptor systems, craving and relapse inspired by acamprosate, clinical research poin...

journal_title：Current pharmaceutical design

authors： Kiefer F,Mann K

更新日期：2010-01-01 00:00:00

abstract：:We have synthesized a novel series of N-substituted sarcosines, analogues of NFPS (N-[3-(biphenyl-4- yloxy)-3-(4-fluorophenyl)propyl]-N-methylglycine), as type-1 glycine transporter (GlyT-1) inhibitors. Several compounds incorporated a diazine ring inhibited recombinant hGlyT-1b expressed permanently in CHO cells and ...

journal_title：Current pharmaceutical design

authors： Harsing LG Jr,Timar J,Szabo G,Udvari S,Nagy KM,Marko B,Zsilla G,Czompa A,Tapolcsanyi P,Kocsis A,Matyus P

更新日期：2015-01-01 00:00:00